Salute e Benessere

Correction: Evaxion to announce business update and third quarter 2025 financial…

Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Thursday November 6, 2025, before opening of the Nasdaq CM.Evaxion’s Executive Management will host a…

Elevaris Medical Devices Names New Chief Engineering and Operations Officer

"Sal brings vast global experience and is incredibly pedigreed in execution, operational excellence, and continuous improvement," said Richard Zrebiec, CEO of Elevaris Medical Devices. "We're excited about the discipline, energy, and vision he brings as we continue to strengthen our engineering and manufacturing capabilities to catapult growth and deliver exceptional value to our customers." "Sal brings vast global experience and is incredibly pedigreed in execution…

Evaxion to announce business update and third quarter 2025 financial results on…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Friday October 31, 2025, before opening of the Nasdaq CM.Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged...

Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI…

CPHI Frankfurt not only a platform for showcasing products and services, but also an important bridge for industry information sharing and resource integration. To this end, our company team actively visited competitor booths, scheduled meetings with clients, and exchanged information with industry partners on global pharmaceutical industry trends and overseas market policy dynamics. This accumulated valuable experience for optimizing our company's subsequent overseas expansion strategy, while…

Global Toothpaste Market Moves Toward Herbal and Online Momentum, says Mordor…

Consumers are increasingly choosing toothpaste made with natural and herbal ingredients, reflecting a growing preference for transparency and health-focused products. This shift is pushing brands to blend traditional remedies with modern science to enhance effectiveness. At the same time, demand for sensitivity-relief toothpaste is rising, driven by aging populations and awareness of oral health. Brands are also ramping up digital marketing through influencers and social media to reach younger…

Bavarian Nordic Awarded New Procurement Framework Contract by the European…

New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of smallpox/mpox vaccine over the next four years.Additional countries have joined the agreement, now providing access to the vaccine for 20 EU member states and other European countries.COPENHAGEN, Denmark, October 31, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today the award of a joint...

Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate…

Mads Kjolby, Co-Founder and Chief Medical Officer at Vesper Bio, said: "Progranulin is vital for maintaining neuronal health. However, progranulin levels in asymptomatic people with GRN mutations are typically half that of people without such mutations. Based on these topline Phase Ib/IIa data, we believe VES001 has the potential to normalise progranulin levels not only in asymptomatic individuals with GRN mutations, but in symptomatic people too, without affecting other sortilin functions…

Implantica publishes Interim Report January - September 2025 (Q3)

Significant events in the third quarter of 2025 Significant events in the third quarter of 2025 Significant events after the end of the period Financial summary third quarter 2025 First nine months Telephone conference Implantica will hold a teleconference on31 October 2025at 15:00 (CET) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast...

DXS International plc ((AQSE: DXSP) - Final Results

DXS INTERNATIONAL PLC(AQSE: DXSP)ANNUAL RESULTSfor the year ended 30 April 2025The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2025. Financial highlights:Revenue increased by 5% to £3,469,917 (2024: £3,308,359). Core recurring revenue model remains resilient.Available cash at...

Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's…

"We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions," said Pei-Jiun Chen, CEO and President of Mycenax. "This collaboration further enhances our technical capabilities and reinforces our commitment to advancing next-generation ADC therapeutics." "We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to…

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare…

$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial foundation toward self-sustainability and the advancement of next wave nanotherapeutic platforms for long-term growthHealthCare Royalty (HCRx) will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3) payable to Nanobiotix under its global...

Correction: Bioretec Ltd's Half-year report 2025

The adjustment and restatement is related to the sales and distribution agreement with Tri-State Biologics ("TSB"), originally announced on 22 November 2024 (the "TSB Distribution Agreement"). The TSB Distribution Agreement was, upon its signing, based on a stocking distribution model, whereby TSB first purchases products from Bioretec for further sale and distribution by TSB to hospitals in the target geography. Following the signing of the TSB Distribution Agreement, a…

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31 stof October 2025Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025.Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8%Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3...

Luxury (High End) Lighting Market to Reach USD 35,220.96 million by 2032…

Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/luxury-lighting-market Browse the report and understand how it can benefit your business strategy -https://www.credenceresearch.com/report/luxury-lighting-market Market Overview The Luxury Lighting Market encompasses high-end fixtures designed not only for illumination but also as premium decorative and architectural elements. These products are characterized by...

Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During…

Atypical Teratoid/Rhabdoid Tumor Market Summary Atypical Teratoid/Rhabdoid Tumor Market Summary Discover the atypical teratoid/rhabdoid tumor new treatment @New Treatments for Atypical Teratoid/Rhabdoid Tumor Key Factors Driving the Growth of the Atypical Teratoid/Rhabdoid Tumor Market Deeper Molecular Understanding and Biomarker-Driven Biology Atypical teratoid/rhabdoid tumor is now understood as a genetically defined disease (most cases driven by bi-allelic loss of...

Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

NyxoahtoReleaseThird Quarter 2025 Financial Results on November 13, 2025Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (EuronextBrussels/Nasdaq:NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management...

BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M

Each Unit will consist of one common share of the Company (each, a "Share") and one common share purchase warrant (each, a "Warrant"), whereby each Warrant will entitle the holder thereof to acquire one additional Share at an exercise price of $0.40 for a period of 24 months from the date of issuance. Each Unit will consist of one common share of the Company (each, a " Share ") and one common share purchase warrant (each, a " Warrant "), whereby each…

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of…

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company’s...

Galapagos Announces Changes to its Board to Accelerate Strategic Focus on…

New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on...

TME Pharma publishes its semi annual results and half-year report

TME Pharma publishes its semi annual results and half-year reportBerlin, Germany , October 30, 2025, 21.00am CET–TME Pharma N.V. (Euronext Growth Paris: ALTME),a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, publishes today its semi annual results and half-year report.The first half of the year was marked by TME Pharma's reorganization to a lower-cost outsourced staffing model. The results of this can be seen...

GENFIT announces intention to voluntarily delist American Depositary Shares from…

GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiencyGENFIT remains listed on the regulated market of Euronext Paris as its primary trading marketLille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT),a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases,...

Thyroid Function Test Market to Reach USD 7,289.26 million by 2032, Growing At…

Market Overview Market Overview The Thyroid Function Test Market encompasses the full range of in-vitro diagnostic (IVD) assays used to assess the performance of the thyroid gland. This gland, located in the neck, produces hormones that regulate the body's metabolism, and its dysfunction can lead to a wide array of health problems. The primary tests in this market measure the levels of key hormones in the blood, including Thyroid-Stimulating Hormone (TSH), Thyroxine (T4), and...

Casino Group expands its Renouveau plan to 2030 and launches work to adapt its…

Casino Group expands its Renouveau plan to 2030 andlaunches work to adapt its financial structure Operating and financial results in line with the targets of the Renouveau 2028 plan Following a year of in-depth transformation in 2024,the first half of 2025 has marked a turning point : for the first time since its restructuring, Casino Group's like-for-like sales and margins are back on the rise:A return to growth for like-for-like net sales: up +2.4% in Q2 and +0.5% in H1;...

Casino Group: Third quarter 2025

THIRD-QUARTER 2025 Continuation of the first half-year's growth dynamic Growth in net sales: +0.5% LFL in Q3 and +0.6% over the first nine months The initial results of the “Renouveau” plan are confirmed, and the Group is again reporting like-for-like net sales growth this quarter.Roll out of the newstore concepts 25 Franprix stores remodelled with the"Oxygène"concept in Q3 (75 to date)3 additional Naturalia stores converted to the"La Ferme"concept in Q3 (23 to...

Altri Comunicati